The voluntary recall was initiated after two product complaints that uncovered a glass particle in one vial and a silicone particle in another one.
“The administration of glass or silicone particulates may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening,” the recall notice reads.
The affected Piperacillin and Tazabactum for Injection lots are PP0317059-A and PP0317012-A. They have expiration dates of February 2019 and August 2019, respectively. They have been distributed to hospitals across the nation.
So far, the drugmaker said it has not received any reports of adverse events.
More articles on pharmacy:
Gilead Sciences CEO to step down after nearly 3 decades
Purdue pharma brings restructuring expert aboard: 6 things to know
Ranier’s Rx Laboratory recalls all sterile compounded drugs
